Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

636
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
636
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

278
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
278
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

146
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
146
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

159
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
159
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

3.4K
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
3.4K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

184
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
184

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cover cropping enhances fruit quality in protected citrus cultivation by modulating rhizosphere microbiome and iron availability.

Frontiers in plant science·2026
Same author

Rhizosphere microbiome influences fruit quality in citrus.

The New phytologist·2026
Same author

[Retracted] Metformin‑induced activation of AMPK inhibits the proliferation and migration of human aortic smooth muscle cells through upregulation of p53 and IFI16.

International journal of molecular medicine·2026
Same author

A proof-of-concept study on high-pressure freezing for cryopreservation.

PNAS nexus·2026
Same author

Antagonism of GPR75 inhibits gestational diabetes mellitus-induced placental tissue injury by preventing activation of the NLRP3 inflammasome.

Tissue & cell·2026
Same author

Intelligent identification of rice leaf diseases via improved faster-RCNN with multi-feature scale fusion.

PloS one·2026

Related Experiment Video

Updated: Dec 27, 2025

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

11.9K

[Clinical practice guidelines for phenylketonuria].

Writing Group For Practice Guidelines For Diagnosis And Treatment Of Genetic Diseases Medical Genetics Branch Of Chinese Medical Association1, Shangzhi Huang, Fang Song

  • 1Peking Union Medical College, WHO Collaborating Center for Community Control of Hereditary Diseases, Beijing 100005, China. hsz_pumc@ibms.pumc.edu.cn.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi = Zhonghua Yixue Yichuanxue Zazhi = Chinese Journal of Medical Genetics
|March 5, 2020
PubMed
Summary

Phenylketonuria (PKU), a common inherited amino acid metabolism disorder, is treatable with early diagnosis and phenylalanine intake control. This guideline standardizes newborn screening and clinical treatment for better patient outcomes.

More Related Videos

A Treatment Package without Escape Extinction to Address Food Selectivity
04:23

A Treatment Package without Escape Extinction to Address Food Selectivity

Published on: August 21, 2015

11.9K
Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

384

Related Experiment Videos

Last Updated: Dec 27, 2025

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

11.9K
A Treatment Package without Escape Extinction to Address Food Selectivity
04:23

A Treatment Package without Escape Extinction to Address Food Selectivity

Published on: August 21, 2015

11.9K
Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

384

Area of Science:

  • Genetics
  • Metabolic Disorders
  • Pediatrics

Background:

  • Phenylketonuria (PKU) is an autosomal recessive hereditary disease affecting amino acid metabolism.
  • PKU incidence in China averages 1/11,000, with regional variations (lower South, higher North/Northwest).
  • PKU is a treatable condition included in national newborn screening programs.

Purpose of the Study:

  • To summarize medical genetics knowledge of PKU.
  • To outline key clinical management strategies for PKU.
  • To enhance diagnostic accuracy and standardize newborn screening and treatment.

Main Methods:

  • Guideline development based on current medical genetics and clinical management data.
  • Review of PKU incidence and regional distribution in China.
  • Emphasis on timely phenylalanine intake control post-diagnosis.

Main Results:

  • PKU diagnosis and management are critical for satisfactory therapeutic effects.
  • Standardized screening and treatment protocols are essential for patient care.
  • Early intervention through controlled phenylalanine intake significantly improves outcomes.

Conclusions:

  • Effective management of PKU relies on accurate diagnosis and standardized treatment protocols.
  • Timely control of phenylalanine intake is crucial for managing PKU in neonates.
  • This guideline aims to improve the overall diagnostic and therapeutic landscape for PKU in China.